摘要
临床上针对基因突变的分子靶向药物在改善肺癌病人的疗效及生存预后方面取得明确成效,筛选阳性突变基因的病人对于实施个体化治疗至关重要。传统基因检测方式存在局限性,近年来基于肿瘤CT征象预测有效基因突变已成为肺癌影像学的研究热点。就肺腺癌CT征象与表皮生长因子受体(EGFR)、间变型淋巴瘤激酶(ALK)、鼠类肉瘤病毒癌基因(KRAS)等常见基因突变相关性的研究进展进行综述。
Molecular targeted agents have obtained remarkable achievements in improving the curative effect and survival prognosis of patients with lung cancer.Screening patients with positive gene mutations is crucial for individual treatment.Recently,estimation of effective gene mutation based on CT characteristics has become a hot area in lung cancer imaging research due to the limitation of traditional gene detection methods.This study summarizes the research progress on relationship between CT characteristics of lung adenocarcinoma and common gene mutation such as epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK)and kirsten rate sarcoma viral oncogene(KRAS).
作者
谢梅
伍建林(审校)
XIE Mei;WU Jianlin(Department of Radiology,Affiliated Zhongshan Hospital of Dalian University,Dalian 116000,China)
出处
《国际医学放射学杂志》
北大核心
2021年第2期188-191,201,共5页
International Journal of Medical Radiology
